AU2004268390B2 - Combinations of a pyrimidine containing NNRTI with RT inhibitors - Google Patents

Combinations of a pyrimidine containing NNRTI with RT inhibitors Download PDF

Info

Publication number
AU2004268390B2
AU2004268390B2 AU2004268390A AU2004268390A AU2004268390B2 AU 2004268390 B2 AU2004268390 B2 AU 2004268390B2 AU 2004268390 A AU2004268390 A AU 2004268390A AU 2004268390 A AU2004268390 A AU 2004268390A AU 2004268390 B2 AU2004268390 B2 AU 2004268390B2
Authority
AU
Australia
Prior art keywords
tmc278
amino
reverse transcriptase
hiv
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004268390A
Other languages
English (en)
Other versions
AU2004268390A1 (en
Inventor
Paul Stoffels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004268390(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of AU2004268390A1 publication Critical patent/AU2004268390A1/en
Assigned to TIBOTEC PHARMACEUTICALS LTD. reassignment TIBOTEC PHARMACEUTICALS LTD. Request for Assignment Assignors: TIBOTEC PHARMACEUTICALS LTD.?
Priority to AU2011201123A priority Critical patent/AU2011201123B2/en
Application granted granted Critical
Publication of AU2004268390B2 publication Critical patent/AU2004268390B2/en
Assigned to JANSSEN SCIENCES IRELAND UC reassignment JANSSEN SCIENCES IRELAND UC Request for Assignment Assignors: TIBOTEC PHARMACEUTICALS LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004268390A 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI with RT inhibitors Expired AU2004268390B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011201123A AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
US60/499,771 2003-09-03
EP03103275.8 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103319.4 2003-09-08
EP03103335.0 2003-09-10
EP03103335 2003-09-10
EP03103668.4 2003-10-02
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
US60/508,486 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011201123A Division AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Publications (2)

Publication Number Publication Date
AU2004268390A1 AU2004268390A1 (en) 2005-03-10
AU2004268390B2 true AU2004268390B2 (en) 2011-03-31

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2004268390A Expired AU2004268390B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2011201123A Expired AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2014203484A Active 2027-01-30 AU2014203484B2 (en) 2003-09-03 2014-06-26 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2016210733A Active 2027-01-30 AU2016210733B2 (en) 2003-09-03 2016-08-05 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2019200813A Abandoned AU2019200813A1 (en) 2003-09-03 2019-02-06 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2011201123A Expired AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2014203484A Active 2027-01-30 AU2014203484B2 (en) 2003-09-03 2014-06-26 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2016210733A Active 2027-01-30 AU2016210733B2 (en) 2003-09-03 2016-08-05 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2019200813A Abandoned AU2019200813A1 (en) 2003-09-03 2019-02-06 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015038I1 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0072I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500053I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I1 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
MX2007002594A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
DK1632232T6 (da) * 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
UA92467C2 (ru) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20080317852A1 (en) * 2005-12-14 2008-12-25 Amar Lulla Pharmaceutical Combination
CA2636436C (en) * 2006-01-20 2014-04-01 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tmc278
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
SG10201408158SA (en) 2008-01-03 2015-03-30 Univ Aix Marseille Composition and methods used during anti-hiv treatment
CN102711834B (zh) * 2008-12-24 2015-08-26 爱尔兰詹森科学公司 治疗hiv的可植入装置
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
TWI556840B (zh) * 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
RS65159B1 (sr) 2016-10-24 2024-02-29 Janssen Sciences Ireland Unlimited Co Disperzibilni sastavi
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
AU2018255954B2 (en) * 2017-04-18 2024-04-04 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001110A2 (en) * 1994-07-01 1996-01-18 Janssen Pharmaceutica N.V. Anti-hiv triple combination
WO1996041634A2 (en) * 1995-06-13 1996-12-27 Sardinian Antiviral Research Consortium - Sarc S.C.R.L. Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
ES2093106T3 (es) 1990-07-19 1996-12-16 Otsuka Pharma Co Ltd Preparacion solida.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP2003509453A (ja) 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
BR0109602A (pt) 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CN1487935A (zh) 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 改良型水溶性药物组合物
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en) 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
AP1927A (en) 2002-11-15 2008-12-10 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PL227577B1 (pl) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AU2005253957B2 (en) 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
EP1872390A2 (en) * 2005-04-11 2008-01-02 The Board of Trustees of the Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
EP1893180A2 (en) 2005-06-07 2008-03-05 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101272848B (zh) 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
CA2636436C (en) 2006-01-20 2014-04-01 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tmc278
PT2040671T (pt) 2006-06-23 2018-03-14 Janssen Sciences Ireland Uc Suspensões aquosas de tmc278
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
US8426434B2 (en) 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001110A2 (en) * 1994-07-01 1996-01-18 Janssen Pharmaceutica N.V. Anti-hiv triple combination
WO1996041634A2 (en) * 1995-06-13 1996-12-27 Sardinian Antiviral Research Consortium - Sarc S.C.R.L. Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
British HIV Association (BHIVA) "guidelines for the treatment of HIV-infected adults with antiretroviral therapy" , HIV Medicine 2001 2:276-313 *
Gilead Initiates Study 934, a 48-week Clinical Trial Evaluating Viread? and EmtrivaTM versus Combivir? 11 August 2003. http://web.archive.org/web/20030818001114/http://www.gilead.com/wt/sec/pr_1060631111 ( [8/05/2009 10:17:46 AM] *
Gulick. R. M, "New antiretroviral drugs" Clinical Microbiology and infection 2003 9(3):186-193 *
http://web.archive.org/web/20020822233346/http://thebody.com/confs/aids2002/pavia5.html [8/05/2009 10:13:20 AM]* *
Pavia, A.T. Abacavir/Lamivudine in Combination with Efavirenz, Amprenavir/Ritonavir or Stavudine. 9 July 2002. *
Scaling up Antiretroviral Therapy in Resource-Limited settings 'Guidelines for a public health approach' World Health Organisation, Executive summary April 2002 *

Also Published As

Publication number Publication date
HUS1500053I1 (hu) 2016-03-29
EP1663240A1 (en) 2006-06-07
US8841310B2 (en) 2014-09-23
CY2015038I2 (el) 2016-08-31
CY2015040I2 (el) 2016-08-31
US20150283135A1 (en) 2015-10-08
US20140349971A1 (en) 2014-11-27
AU2011201123B2 (en) 2013-10-10
NO2014030I1 (no) 2015-01-05
AU2016210733A1 (en) 2016-08-25
FR15C0073I1 (enExample) 2015-04-12
NL300768I1 (enExample) 2015-12-16
FR15C0072I2 (fr) 2019-05-17
JP5820045B2 (ja) 2015-11-24
FR16C1022I1 (fr) 2017-02-03
IL213104A0 (en) 2011-07-31
LU92853I2 (fr) 2015-12-21
FR15C0071I1 (enExample) 2015-04-12
WO2005021001A1 (en) 2005-03-10
CN101060844A (zh) 2007-10-24
US20100029591A1 (en) 2010-02-04
CY2015040I1 (el) 2016-08-31
NO2014031I2 (no) 2014-12-18
CA2537095C (en) 2012-05-29
CY2016048I2 (el) 2017-07-12
NO2014032I1 (no) 2015-01-05
NO2016025I1 (enExample) 2016-12-20
CY2015039I2 (el) 2016-08-31
PL1663240T3 (pl) 2015-10-30
US20190216807A1 (en) 2019-07-18
MXPA06002437A (es) 2006-06-20
NO2014032I2 (no) 2014-12-18
AP2109A (en) 2010-02-26
FI1663240T4 (fi) 2023-04-25
HK1092698A1 (en) 2007-02-16
NO2014030I2 (no) 2014-12-18
LTPA2016045I1 (lt) 2017-01-10
HRP20150798T4 (hr) 2023-06-09
FR15C0071I2 (fr) 2016-02-12
AU2014203484B2 (en) 2016-09-29
LU92855I2 (fr) 2015-12-21
CY2015038I1 (el) 2016-08-31
KR20060090658A (ko) 2006-08-14
AU2011201123A1 (en) 2011-04-07
AU2019200813A1 (en) 2019-02-28
CN101060844B (zh) 2012-01-04
NO20061374L (no) 2006-03-27
PL1663240T5 (pl) 2024-02-26
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
FR16C1024I1 (fr) 2017-02-03
HRP20150798T1 (hr) 2015-09-11
LTC1663240I2 (lt) 2022-05-25
AU2014203484A1 (en) 2014-07-17
LU92854I2 (fr) 2015-12-21
FR15C0073I2 (fr) 2016-02-12
NZ545306A (en) 2009-11-27
US20180228800A1 (en) 2018-08-16
AP2006003551A0 (en) 2006-04-30
CY2016049I2 (el) 2017-07-12
LTPA2016044I1 (lt) 2017-01-10
CY2015039I1 (el) 2016-08-31
BE2015C053I2 (enExample) 2023-12-14
CY2016049I1 (el) 2017-07-12
HUS1600059I1 (hu) 2017-02-28
JP2015044839A (ja) 2015-03-12
AU2004268390A1 (en) 2005-03-10
NO334877B1 (no) 2014-06-23
JP2007520443A (ja) 2007-07-26
JP5507791B2 (ja) 2014-05-28
CY2016048I1 (el) 2017-07-12
EP1663240B1 (en) 2015-04-22
IL173438A (en) 2012-03-29
HUS1500052I1 (hu) 2016-03-29
MY169670A (en) 2019-05-08
NL300781I1 (enExample) 2016-04-19
EP1663240B2 (en) 2023-03-01
US20200171027A1 (en) 2020-06-04
IL173438A0 (en) 2006-06-11
CA2537095A1 (en) 2005-03-10
NO2014031I1 (no) 2015-01-05
IL213104A (en) 2016-02-29
HUS1600058I1 (hu) 2017-02-28
FR15C0072I1 (enExample) 2015-04-12
AU2016210733B2 (en) 2018-11-08
NO2016026I1 (no) 2016-12-20
US20220008417A1 (en) 2022-01-13
JP2012051915A (ja) 2012-03-15
HUS1500054I1 (hu) 2016-03-29
NL300768I2 (nl) 2023-08-09
US20170100398A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
AU2011201123B2 (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors
DK1663240T3 (en) COMBINATIONS OF A PYRIMIDINE-CONTAINING NNRTI WITH RT INHIBITORS
HK1092698B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
HK1165277A (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
ZA200601820B (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTOR NAME FROM STOFFELS, PAUL? TO STOFFELS, PAUL

TC Change of applicant's name (sec. 104)

Owner name: TIBOTEC PHARMACEUTICALS LTD.

Free format text: FORMER NAME: TIBOTEC PHARMACEUTICALS LTD.?

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: JANSSEN SCIENCES IRELAND UC

Free format text: FORMER OWNER WAS: TIBOTEC PHARMACEUTICALS LTD.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired